The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Citing Indian Council for Medical Research (ICMR) and published studies, Dr Bhavesh Kotak, Head of Medical Affairs at Dr ...